LBA23A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL TRACT CANCER

Abstract Aim: Tumors use the PD-1 receptor-ligand pathway to evade immune surveillance. The anti-PD-1 monoclonal antibody pembro has demonstrated antitumor activity in advanced solid tumors. We assessed the safety, tolerability, and antitumor activity of pembro in pts with recurrent or metastatic ur...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (suppl_4)
Hauptverfasser:	Plimack, E.R., Gupta, S., Bellmunt, J., Berger, R., Montgomery, B., Gonzalez, E.J., Pulini, J., Dolled-Filhart, M., Emancipator, K., Pathiraja, K., Gause, C., Perini, R., Cheng, J., O'Donnell, P.H.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!